Study design and rationale of "Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial

Study design and rationale of "Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial

Item

http://www.wikidata.org/entity/Q34552698

Q34552698

about

The prevention and regression of atherosclerotic plaques: emerging treatments.A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol.Oral absorption enhancement of probucol by PEGylated G5 PAMAM dendrimer modified nanoliposomes The role of complement in the development and manifestation of murine atherogenic inflammation: novel avenues.Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study.

P2860

Q27691367-258CA345-4395-40C8-881E-5B2916A35A48 Q36313643-5932A45A-C8EB-44BE-90D5-1FF285670BD5 Q36628814-77D62596-1CDC-427B-B656-1B1E683E95F6 Q37960811-C9E4FC82-DBE7-4F54-B3EB-7ACAAD17BD65 Q42759537-83FDD26B-008F-4934-B1C8-E08B074644F8

P2860

Study design and rationale of "Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial

Item

http://www.wikidata.org/entity/Q34552698

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Study design and rationale of ...... led multicenter clinical trial

@ast

Study design and rationale of ...... led multicenter clinical trial

@en

Study design and rationale of ...... lization and lesion REgression

@nl

type

Item

label

Study design and rationale of ...... led multicenter clinical trial

@ast

Study design and rationale of ...... led multicenter clinical trial

@en

Study design and rationale of ...... lization and lesion REgression

@nl

prefLabel

Study design and rationale of ...... led multicenter clinical trial

@ast

Study design and rationale of ...... led multicenter clinical trial

@en

Study design and rationale of ...... lization and lesion REgression

@nl

P1476

Study design and rationale of ...... led multicenter clinical trial

@en

P2093

Byeong-Keuk Kim

http://www.w3.org/2001/XMLSchema#string

Byoung Kwon Lee

http://www.w3.org/2001/XMLSchema#string

Jong Ho Lee

http://www.w3.org/2001/XMLSchema#string

Myoungsook Lee

http://www.w3.org/2001/XMLSchema#string

Peter J Fitzerald

http://www.w3.org/2001/XMLSchema#string

SECURE Investigators

http://www.w3.org/2001/XMLSchema#string

Sang Wook Kim

http://www.w3.org/2001/XMLSchema#string

Seung Hyuk Choi

http://www.w3.org/2001/XMLSchema#string

Won-Heum Shim

http://www.w3.org/2001/XMLSchema#string

Woong Chol Kang

http://www.w3.org/2001/XMLSchema#string

P2860

Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

Coronary plaque classification with intravascular ultrasound radiofrequency data analysis.

Metabolism of high density lipoprotein subfractions.

Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.

The apolipoprotein A5 -1131T>C promoter polymorphism in Koreans: association with plasma APOA5 and serum triglyceride concentrations, LDL particle size and coronary artery disease

The vascular effects of cilostazol.

Is it LDL particle size or number that correlates with risk for cardiovascular disease?

P2888

1745-6215-12-10

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1745-6215-12-10

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49747656

http://www.w3.org/2001/XMLSchema#string

P6179

1008634850

http://www.w3.org/2001/XMLSchema#string

P698

21226953

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

3033833

http://www.w3.org/2001/XMLSchema#string

Study design and rationale of "Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial

about

P2860

P2860

Study design and rationale of "Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P921

P932